Black Diamond Therapeutics Inc

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on discovering and developing MasterKey therapies for patients with genetically defined tumors. Its lead candidate, silevertinib, is a brain-penetrant epidermal growth factor receptor MasterKey inhibitor in Phase 2 trials for EGFR-mutant non-small cell lung cancer and glioblastoma. The company is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors (Phase 1), and BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4 (preclinical). Formerly ASET Therapeutics, Inc., it changed its name to Black Diamond Therapeutics, Inc. in January 2018, was incorporated in 2014, and is headquartered in Cambridge, Massachusetts.